Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLH28J)

Drug Name
REGN 3051 Drug Info
Indication
Disease Entry ICD 11 Status REF
Middle East Respiratory Syndrome (MERS) 1D64 Discontinued in Phase 1 [1]
Therapeutic Class
Antiviral Agents
Cross-matching ID
TTD Drug ID
DMLH28J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting MERS-CoV spike glycoprotein (S)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nafamostat DMU1XOD Pancreatitis DC31-DC34 Approved [3]
REGN 3048 DMW08TD Middle East Respiratory Syndrome (MERS) 1D64 Discontinue in Phase 1 Trial [2]
PMID26911565-peptide-P9 DMUH012 Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [4]
MERS-five-helix bundle DMG5YRP Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [5]
Alpha-Helical lipopeptides LLS DM3WVM4 Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [6]
Peptide P21S10 DMMWQTI Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [7]
Alpha-Helical lipopeptides IIS DM1MGBX Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [6]
Alpha-Helical lipopeptides IIK DMVSKQF Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [6]
Alpha-Helical lipopeptides FFS DMATQB7 Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [6]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MERS-CoV spike glycoprotein (S) TT85VHW A0A140AYZ5_9BETC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health.
2 Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112.
3 Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
4 A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008.
5 Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Viruses. 2017 Sep 14;9(9). pii: E255.
6 De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745.
7 Discovery of Hydrocarbon-Stapled Short -Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. J Med Chem. 2018 Mar 8;61(5):2018-2026.